NCT05113784View on ClinicalTrials.gov

the Safety and Efficacy of Meplazumab in Patients With COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

September 20, 2022

Study Completion Date

October 8, 2022

Conditions
Covid19
Interventions
DRUG

Meplazumab for Injection

humanized antibody target CD147

DRUG

Sterile normal saline (0.9%)

Sterile normal saline (0.9%)

Trial Locations (2)

Unknown

Shanghai Public Health Clinical Center, Shanghai

The Third People's Hospital Of Shenzhen, Shenzhen

All Listed Sponsors
lead

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

INDUSTRY